Health

Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

SHANGHAI, Aug. 9, 2024 /PRNewswire/ -- Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the launch ofAsia's first international multi-center clinical study of Percutaneous Pulmonary Artery ...

2024-08-09 17:09 4789

MALAYSIA HEALTHCARE TRAVEL COUNCIL (MHTC) CONTINUES TO ENHANCE AND ELEVATE THEIR "EXPERIENCE MALAYSIA HEALTHCARE (EMH) STORIES" SERIES WITH EPISODE 3

KUALA LUMPUR, Malaysia, Aug. 8, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) continues their ongoing efforts to enhance and elevate their "Experience Malaysia Healthcare (EMH) Stories" with the third episode featuring Prof. Dato Sri Dr.Alwi Mohamed Yunus from Institut Jantung Ne...

2024-08-08 16:10 2655

Morinaga Nutritional Foods Vietnam Promoting Sustainable Development with Advanced Technology, Unique functional ingredient, and Green Production

HANOI, Vietnam, Aug. 8, 2024 /PRNewswire/ -- Morinaga Nutritional Foods Vietnam (MNFV), an integral part of Morinaga Milk Industry Group - one of the leading company in the dairy and nutrition industry inJapan renowned for over a century of innovation and quality - embodies a commitment to excell...

2024-08-08 10:56 2437

Fierce Competition and Technological Innovation Drive Diabetes Care Devices Market Towards Explosive Growth

OEMs Leading the Charge with AI-Equipped Technology and Novel Business Strategies SAN ANTONIO, Aug. 8, 2024 /PRNewswire/ -- The diabetes care devices industry is witnessing a dynamic evolution, marked by intense competition among established players and emerging start-ups. Original Equipment Man...

2024-08-08 00:00 2008

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell  therapy IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of...

2024-08-07 23:37 2593

Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months

* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...

2024-08-07 10:05 2278

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

* Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] * Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mo...

2024-08-07 09:00 2208

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 2266

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 1982

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2024-08-06 18:47 2115

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept h...

2024-08-06 17:00 2036

Ping An Ranked in the Fortune Global 500 for the 15th Consecutive Year

HONG KONG and SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) is 53rd on the Fortune 500 list for 2024. With revenue of USD14.58 billion, the Group ranked 9th among global financial e...

2024-08-06 15:10 3493

The Adecco Group: Q2 2024 Results

Further market share gains and disciplined cost management; G&A savings above-target ZURICH, Aug. 6, 2024 /PRNewswire/ -- * Revenues -2% yoy in challenging markets; Group relative revenue growth +375 bps and Adecco GBU +220 bps * Revenues by GBU, Adecco -2% yoy, Akkodis -2% yoy, LHH -7% yoy ...

2024-08-06 12:45 1532

Terumo Establishes Corporate Venture Capital "Terumo Ventures"

TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading the Group's venture investments, as a department within Terumo Americas Holding, Inc. Terumo Vent...

2024-08-06 09:00 2581

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO ® in other ASEAN markets including Thailand and Indonesia with app...

2024-08-06 08:00 1803

VISTA Eye Specialist Launches Corporate Program to Combat Rising Workplace Eye Issues

PETALING JAYA, Malaysia, Aug. 6, 2024 /PRNewswire/ -- VISTA Eye Specialist ("VISTA"), a leading provider of eye care services, today announced the launch of its Premier Corporate Partner Program. This initiative aims to combat the rising incidence of eye diseases, including dry eye caused by prol...

2024-08-06 08:00 1715

Everest Medicines to Announce 2024 Interim Results on August 28, 2024

SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...

2024-08-06 07:30 2911

Seegene Showcased its Multiplex Technology at ADLM 2024

-  Exhibited multiplex PCR testing technologies that provide comprehensive results from a single test -  Presented high-multiplex assays and automated testing systems -  Introduced the SG OneSystem™ business, the company's global technology-sharing initiative SEOUL, South Korea, Aug. 5, 2024 /P...

2024-08-05 21:00 2161

Everise Honored at Stevie® Awards for Great Employers With Multiple Wins

PLANTATION, Fla., Aug. 5, 2024 /PRNewswire/ -- Everise has been named winner in several categories in the annual Stevie Awards for Great Employers, which recognize the world's best employers and teams who help to create and drive great places to work. Everise was awarded with Gold and Silver wins...

2024-08-05 21:00 18764

Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced f...

2024-08-05 21:00 1549
1 ... 30313233343536 ... 580